 |
3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt |
|---|---|
| Trade Name | |
| Orphan Indication | Idiopathic pulmonary fibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2017-01-25 00:00:00 |
| Sponsor | Vicore Pharma;c/o AstraZeneca, Pepparedsleden 1;M�lndal |
